1XH5 image
Entry Detail
PDB ID:
1XH5
Title:
Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
Biological Source:
PDB Version:
Deposition Date:
2004-09-17
Release Date:
2005-09-17
Method Details:
Experimental Method:
Resolution:
2.05 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:cAMP-dependent protein kinase, alpha-catalytic subunit
Chain IDs:A
Chain Length:350
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:cAMP-dependent protein kinase inhibitor, alpha form
Chain IDs:B
Chain Length:20
Number of Molecules:1
Biological Source:synthetic construct
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
SEP A SER PHOSPHOSERINE
TPO A THR PHOSPHOTHREONINE
Primary Citation
Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants
J.Med.Chem. 48 163 170 (2005)
PMID: 15634010 DOI: 10.1021/jm049701n

Abstact

Protein kinase B (PKB)-selective inhibitors were designed, synthesized, and cocrystallized using the AGC kinase family protein kinase A (PKA, often called cAMP-dependent protein kinase); PKA has been used as a surrogate for other members of this family and indeed for protein kinases in general. The high homology between PKA and PKB includes very similar ATP binding sites and hence similar binding pockets for inhibitors, with only few amino acids that differ between the two kinases. A series of these sites were mutated in PKA in order to improve the surrogate model for a design of PKB-selective inhibitors. Namely, the PKA to PKB exchanges F187L and Q84E enable the design of the selective inhibitors described herein which mimic ATP but extend further into a site not occupied by ATP. In this pocket, selectivity over PKA can be achieved by the introduction of bulkier substituents. Analysis of the cocrystal structures and binding studies were performed to rationalize the selectivity and improve the design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures